Furthermore, it also enabled us to determine if there were differences in phenotype- or treatment efficacy compared to other mouse models of RASopathies caused by mutations in up-stream regulators of HRAS protein, such as NF1, SHP2/PTPN11, and SPRED1. This evidence concerns the gene HRAS and RASopathy.